EWS-ETS oncoproteins: The linchpins of Ewing tumors

被引:126
作者
Janknecht, R [1 ]
机构
[1] Mayo Clin Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
关键词
cancer; Ewing's sarcoma protein; FUS; gene transcription; RNA splicing;
D O I
10.1016/j.gene.2005.08.007
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Ewing tumors, which comprise Ewing's sarcoma and peripheral primitive neuroectodermal tumors, are highly aggressive and mostly affect children and adolescents. Their molecular signature is a chromosomal translocation leading to the generation of EWS-ETS (or very rarely FUS-ETS) fusion proteins that are capable of transforming cells. These oncoproteins act as aberrant transcription factors due to the fusion of an ETS DNA binding domain to a highly potent EWS (or FUS) transactivation domain. Accordingly, many EWS-ETS target genes have been identified whose dysregulation could contribute to the development of tumor formation. Furthermore, EWS-ETS oncoproteins may impact on RNA splicing or affect other proteins through disturbing their ability to form functional complexes. The molecular knowledge gained so far from studying EWS-ETS oncoproteins has not only broadened our understanding of Ewing tumors but also improved the diagnosis of these highly undifferentiated tumors. In addition, several potential prognostic markers have been uncovered and novel therapies are suggested that may improve the still dismal survival rate of Ewing tumor patients. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 236 条
[71]   Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia [J].
Hart, A ;
Melet, F ;
Grossfeld, P ;
Chien, K ;
Jones, C ;
Tunnacliffe, A ;
Favier, R ;
Bernstein, A .
IMMUNITY, 2000, 13 (02) :167-177
[72]  
HART AH, 1995, ONCOGENE, V10, P1423
[73]   Descriptive epidemiology of Ewing tumors -: Analyses of the German patients of (EI)CESS 1980-1997 [J].
Hense, HW ;
Ahrens, S ;
Paulussen, M ;
Lehnert, M ;
Jürgens, H .
KLINISCHE PADIATRIE, 1999, 211 (04) :271-275
[74]   Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death [J].
Hicks, GG ;
Singh, N ;
Nashabi, A ;
Mai, S ;
Bozek, G ;
Klewes, L ;
Arapovic, D ;
White, EK ;
Koury, MJ ;
Oltz, EM ;
Van Kaer, L ;
Ruley, HE .
NATURE GENETICS, 2000, 24 (02) :175-179
[75]   Telomerase as tumor marker [J].
Hiyama, E ;
Hiyama, K .
CANCER LETTERS, 2003, 194 (02) :221-233
[76]   Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors [J].
Hollenhorst, PC ;
Jones, DA ;
Graves, BJ .
NUCLEIC ACIDS RESEARCH, 2004, 32 (18) :5693-5702
[77]   Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors [J].
Holzer, G ;
Obermair, A ;
Koschat, M ;
Preyer, O ;
Kotz, R ;
Trieb, K .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (06) :601-604
[78]   Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion:: A highly lethal subset associated with poor chemoresponse [J].
Huang, HY ;
Illei, PB ;
Zhao, ZQ ;
Mazumdar, M ;
Huvos, AG ;
Healey, JH ;
Wexler, LH ;
Gorlick, R ;
Meyers, P ;
Ladanyi, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :548-558
[79]  
ICHIKAWA H, 1994, CANCER RES, V54, P2865
[80]  
Im YH, 2000, CANCER RES, V60, P1536